The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

DKK 2016 | Incorporating monoclonal antibodies in the treatment algorithm of multiple myeloma

Name: Incorporating monoclonal antibodies in the treatment algorithm of multiple myeloma
Uploaded: 2016-02-25T00:00:00Z
Duration: 2 min 12 s
Description: Monoclonal antibodies have been recognised for their significant potential for the treatment of multiple myeloma. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from the University of Cologne, Cologne, Germany, reviews the clinical development of elotuzumab, which targets CS1, and daratumumab, which targets CD38.

Christof Scheid • 25 Feb 2016

DKK 2016

Multiple Myeloma Antibodies Daratumumab Elotuzumab

Monoclonal antibodies have been recognised for their significant potential for the treatment of multiple myeloma. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from the University of Cologne, Cologne, Germany, reviews the clinical development of elotuzumab, which targets CS1, and daratumumab, which targets CD38.